Immix Biopharma, Inc. Stock Price

NasdaqCM:IMMX Community·US$208.4m Market Cap

0 Narratives written by author
0 Comments on narratives written by author
2 Fair Values set on narratives written by author

Create a narrative

IMMX Share Price Performance

US$5.94

3.65 (159.39%)

US$5.94

3.65 (159.39%)

US$5.94

Wed, 17 Dec 25

Share Pricen/a

IMMX Community Narratives

There are no narratives available yet.

Create a narrative

There are no community narratives available.

Trending Discussion

Snowflake Analysis

Flawless balance sheet with moderate risk.

5 Risks

0 Rewards

View Full Analysis

Immix Biopharma, Inc. Key Details

Last Reported Earnings

Sep 30, 2025

Next Reporting Earnings

n/a

: -0.70
: 0%
: 0%
: 0%

View Full Analysis

About IMMX

Founded: 2012
Employees: 20
CEO: Ilya Rachman
WebsiteView website: www.immixbio.com

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company’ lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.